Home > News > Headline News > Archive

Click on title to read the full article.

Dose-Adjusting Capecitabine (Xeloda) Minimizes Adverse Effects While Maintaining Efficacy

November 30, 2011

By Leonard, Hennessy, Blum & O'Shaughnessy, Clinical Breast Cancer Journal

Together, these data support the practice of dose-reducing capecitabine, including the possibility of starting at a lower dose(<1250 mg/m2 twice daily), to reduce the incidence of adverse events without compromising efficacy.

Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial

November 30, 2011

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced 23.2 month median overall survival (OS) from a single-arm Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with locally advanced or metastatic breast cancer.

Maggie Daley inspired countless breast cancer patients

November 28, 2011

By Lolly Bowean, John Byrne and Robert McCoppin, Chicago Tribune

As word of Daley's death spread Friday, the sad news was especially gripping for Chicago-area cancer survivors. In Maggie Daley, many saw a woman who fought the battle with dignity and grace, and who never let her illness overtake her radiant spirit.

‘Medical miracle’: Maggie Daley lived long time for breast cancer patient

November 25, 2011

By Kara Spak and Fran Spielman, Chicago Sun Times

Her husband called her a fighter. Her doctor called her a medical miracle. Maggie Daley, who died Thursday after more than tripling the average survival rate for those with a metastatic breast cancer diagnosis, said she simply was part of a group ready to face what life threw at them. “I have a lot of challenges ahead,” Mrs. Daley said in May, at an event celebrating her husband’s tenure as mayor. “But anybody who has cancer has the same experience. We’re a mighty group. I’m not alone. I’m one of many.”

New Guidelines on Treatment of Advanced Breast Cancer

November 24, 2011

By Zosia Chustecka

New guidelines for the treatment of advanced breast cancer, specifically metastatic breast cancer, have been developed by an international group of breast cancer experts.

FDA Revokes Avastin Approval for Breast Cancer

November 19, 2011

By Emily P. Walker

The FDA has announced that bevacizumab (Avastin) is no longer approved for the treatment of breast cancer. The Genentech drug retains its indications for colon, lung, kidney, and brain cancer and will remain on the market.

Advanced Breast Cancer - First Worldwide Guidelines

November 15, 2011

By Grace Rattue

Recently (3-5 November) at a conference in Lisbon, Portugal, experts from around the world agreed on the world's first consensus how to treat and help individuals suffering with advanced breast cancer.

Benefit of novel drug in breast cancer seen in blood within weeks

November 14, 2011

By Jeremy Moore

Clinical benefit from use of a novel histone deacetylase inhibitor drug may be determined by examining blood cells days after a patient receives treatment. The drug, entinostat, is the first histone deacetylase inhibitor successfully tested in a randomized, placebo-controlled study in metastatic breast cancer — and is the first to show that clinical outcome can be predicted shortly after administration.

Trastuzumab With Chemo beats Sequential Administration in Breast Cancer

November 13, 2011

By Anna Azvolinsky, PhD

The results of a trial comparing concurrent versus sequential trastuzumab(Drug information on trastuzumab) and chemotherapy as adjuvant treatment of breast cancer has shown an improved efficacy without increased toxicity for the concurrent regimen. As the authors of the accompanying editorial (DOI: 10.1200/JCO.2011.38.3836) point out, this result is likely to thwart additional trials comparing the two types of administration. The editorial authors along with the authors of the research suggest that the concurrent schedule should be adopted as best standard of care.

NICE (inUK) won’t back Faslodex in breast cancer

November 11, 2011

By Ben Adams

NICE has not recommended AstraZeneca’s breast cancer drug Faslodex as it says the drug is no better than existing treatments. The final draft guidance does not recommend Faslodex (fulvestrant) as an alternative to aromatase inhibitors for postmenopausal women who have oestrogen-receptor-positive locally advanced or metastatic breast cancer, who have received an anti-oestrogen therapy.

 1 2 >